Theophylline

Theophylline is one of the original nootropic stimulants; it is essentially caffeine's older, sharper cousin, and it opens the airways while it wakes you up. The genuinely interesting part is the low-dose anti-inflammatory angle; at concentrations well below the old bronchodilator range it switches HDAC2 back on and hands corticosteroids their sensitivity back, which is a trick pretty much nothing else in the xanthine family pulls off.

The respiratory drive it provides is real and well documented, and it has decades of clinical mileage behind it. The trade-off deserves to be stated plainly though; it has a narrow therapeutic window, blood levels matter, and it interacts with a long list of drugs, so it is a compound you respect rather than casually stack. Doxofylline exists precisely because people wanted the benefits with fewer of the jitters and heart effects. For the airways-plus-alertness combination, theophylline is hands down a classic that still earns its place.

Theophylline has a narrow therapeutic window and side effects track closely with plasma concentration. Lower-range levels can cause nausea, vomiting, headache, tremor and insomnia; higher levels risk cardiac arrhythmias and seizures, driven largely by adenosine A1-receptor antagonism. It is metabolized mainly by hepatic CYP1A2, so levels are affected by smoking, fever, liver disease and a long list of interacting drugs (for example fluoroquinolones, cimetidine and macrolides), which is why blood monitoring was standard in its heavy-use era. The large TWICS randomized trial (2018) found that adding low-dose theophylline to inhaled corticosteroids did NOT reduce COPD exacerbations, tempering the earlier enthusiasm for its steroid-sensitizing mechanism as a routine clinical strategy. It is not risk-free and is best used under medical supervision.

Theophylline has a narrow therapeutic index and is cleared mainly by CYP1A2, a combination that makes it one of the most interaction prone drugs still in use. A modest shift in clearance moves it from effective to toxic, with nausea and tremor first, then tachyarrhythmia and seizures.

Inhibitors of CYP1A2 raise concentrations: fluvoxamine is the strongest, followed by ciprofloxacin and enoxacin, cimetidine, erythromycin and clarithromycin, zileuton, ticlopidine, propranolol and oral contraceptives. Inducers do the reverse and cause silent treatment failure: rifampin, phenytoin, carbamazepine, phenobarbital and ritonavir. Tobacco and cannabis smoke induce CYP1A2 strongly, so smokers clear theophylline far faster, and concentrations climb when smoking stops.

Theophylline is also an adenosine receptor antagonist, a pharmacodynamic interaction rather than a metabolic one: it blunts adenosine and dipyridamole in cardiac stress testing and reduces adenosine's ability to terminate supraventricular tachycardia. Added to beta agonists it worsens tachycardia and hypokalemia, and it increases renal lithium clearance enough to push lithium below its therapeutic range.

Checking a whole stack? Run it through interactions + stacks.